<SUBMISSION>
<ACCESSION-NUMBER>0001144204-03-007811
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20031121
<ITEMS>5
<ITEMS>7
<FILING-DATE>20031124
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<IRS-NUMBER>510402415
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>031019327
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.txt
<TEXT>

<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest reported)           November 21, 2003
                                           -----------------------------------

                           Advanced Biotherapy, Inc.
             (Exact name of registrant as specified in its chapter)

         Delaware                     0-26323                  51-0402415
     ------------------           -----------------      ---------------------
(State or other jurisdiction        (Commission          (IRS Employer
             of incorporation)       File Number)         Identification No.)

6355 Topanga Canyon Boulevard, Suite 510                            91367
----------------------------------------                            -----
Woodland Hills, California                                       (Zip Code)
--------------------------
(Address of principal executive offices)

Registrant's telephone number, including area code   (818) 883-6716
                                                   --------------------


<PAGE>

Item 5.  OTHER EVENTS.

         The Registrant reported that President and CEO Edmond Buccellato has
joined the delegation to develop international biotechnology relationships
between the United states and Taiwan.


Item 7.  FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

Designation                      Description of Exhibit
-----------                      ----------------------
99.1                             Press Release dated 11/21/03



<PAGE>


EXHIBIT 99.1

                                   Signatures

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   ADVANCED BIOTHERAPY, INC.
                                   (Registrant)


Date:    November 21, 2003         By: /s/Edmond Buccellato
                                       --------------------------------------
                                       Edmond Buccellato, President and CEO




                                INDEX TO EXHIBITS

Designation                      Description of Exhibit
-----------                      ----------------------
99.1                             Press Release dated 11/21/03




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex-99_1.txt
<TEXT>
<PAGE>
EXHIBIT 99.1



                                    ADVANCED BIOTHERAPY, INC.
                                    Administration
                                    6355 Topanga Canyon Boulevard, Suite 510
                                    Woodland Hills, California  91367

                                    Laboratories
                                    9110 Red Branch Rd.
                                    Columbia, MD   21045

                                    Telephone 818-883-6716
                                    Fax           818-883-3353
                                    www.advancedbiotherapy.com


                              FOR IMMEDIATE RELEASE

   Advanced Biotherapy's CEO Asked to Join U.S. Representative Roscoe Bartlett
                      and Scientific Delegation in Taiwan


Taipei, Taiwan -- (BUSINESS WIRE)--November 21, 2003

Edmond  Buccellato  joins  delegation  in  furtherance  of promoting  free trade
agreement negotiations between United States and Taiwan

Advanced  Biotherapy Inc.  (OTCBB:  ADVB - News) and the Office of United States
Congressman Roscoe Bartlett - Joint Press Release

Advanced  Biotherapy,  Inc., a developer  of antibody  therapies to treat severe
autoimmune  diseases,  reported today that Edmond  Buccellato,  Chief  Executive
Officer and Chairman of the Board of Directors  has joined a team of US business
executives,  at  the  request  of  United  States  Congressman  Roscoe  Bartlett
(R-6-MD),  to meet in Taiwan with  representatives  of the country's Ministry of
Economic   Affairs  and  other  Taiwanese   government  and  business   leaders.
Congressman   Bartlett,   who  serves  as  Chairman  of  the  Projection  Forces
Subcommittee  of the  U.S.  House  Armed  Services  Committee,  is one of  three
scientists  in  Congress  and  also  serves  on  the  Science   Committee.   The
delegation's  task is to help foster future economic  relationships  between the
United  States and  Taiwan,  including  the  creation of  biotechnology  related
employment opportunities in western Maryland.

Mr.  Buccellato  stated,  "I am honored to serve on this  delegation  to develop
international  biotechnology relationships between the United States and Taiwan.
Our  country's  pool of  scientific  and business  talent in  biotechnology  has
resulted  in  novel  and  effective  treatments  for a host of  medical  needs -
achievements that are unparalleled in the world. Taiwan's emergence as a vibrant
and innovative  biotechnology  hub for the Pacific Rim creates an opportunity to
forge  scientific  alliances  that  may  be  commercially  attractive  for  both
countries,  and more importantly,  result in continued and effective development
of  medical   treatments  for  those  who  suffer  from   life-threatening   and
catastrophic  diseases  throughout the world.  We look forward to productive and
fruitful discussions while we are guests in this very progressive country."


<PAGE>




Congressman  Bartlett  stated "I want to thank Mr.  Buccellato  for joining this
delegation.  His Company's  experience and boldness under the direction of their
Senior   Scientist,   Dr.  Simon   Skurkovich,   in  cultivating   international
biotechnology  relationships in Eastern Europe is very encouraging.  The purpose
of this visit is to demonstrate  the vast economic  interest and mutual benefits
the State of Maryland and the United  States  offers to  business,  industry and
investors  from  Taiwan.   Promoting  knowledge  of  the  astonishing  array  of
scientific  and  entrepreneurial  talent and the  outstanding  and educated work
force in Western  Maryland among leading  biotech  businesses,  such as Advanced
Biotherapy,   Inc.,   to  our  allies  in  Taiwan  will  help  create  more  job
opportunities.  I am confident that this effort will also further strengthen the
potential for successful negotiations of a U.S.-Taiwan Free Trade Agreement.

About Advanced Biotherapy
Advanced Biotherapy, Inc., located in Los Angeles, with research laboratories in
Columbia,  Maryland, is pioneering the development of new antibody therapies for
treating severe and widespread autoimmune diseases. Its investigational antibody
therapies  attack  autoimmune  diseases at their source,  neutralizing  biologic
imbalances  that  impair  immune  system  function.  The  Company's  approach to
treating  autoimmune  diseases  has shown  encouraging  and  sometimes  striking
results in  investigational  clinical trials in rheumatoid  arthritis,  multiple
sclerosis,   various  skin  diseases  (including  psoriasis,   alopecia  areata,
vitiligo,  pemphigus,  and epidermolysis  bullosa), type 1 diabetes, and corneal
transplant  rejection.  Core  technology  is  protected  under U.S.  patents and
patents  pending for the  exclusive  use of a class of antibodies to the protein
known  as  interferon-gamma  and  antibodies  to other  proteins,  such as tumor
necrosis factor-alpha, for treating a range of autoimmune diseases.

Statements made in this news release,  other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated  results or
other expectations  expressed in our forward-looking  statements.  Some of these
forward-looking  statements  may be  identified  by  the  use  of  words  in the
statements such as  "anticipate,"  "estimate,"  "expect,"  "project,"  "intend,"
"plan,"  "believe"  or other words and terms of similar  meaning.  The risks and
uncertainties  which may affect the  development,  operations and results of our
business  include,  but are not limited to the following:  risks associated with
clinical trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory  approval process,  the risks of competitive
products,  the risks of our current capital  resources,  the uncertainties as to
the availability of future capital and our future capital requirements,  and the
risks associated with the extent and breadth of the Company's patent  portfolio.
The foregoing  discussion of the pending clinical  investigations and the effect
of the patents issued and pending  involves risks and  uncertainties,  including
but not limited to the risks that third parties may be successful in challenging
such  patents;  or that  granted  claims  may be  held  invalid  or  interpreted
differently by a court of law; or that new  technologies  will be developed that
are  superior in treating  the diseases  targeted by Advanced  Biotherapy,  Inc.
Readers are cautioned not to place reliance on these forward-looking statements,
which  speak only as of the date the  statements  were made.  See the  Company's
public  filings  with  the  Securities  and  Exchange   Commission  for  further
information  about risks and  uncertainties  that may affect the Company and the
results or expectations expressed in our forward-looking  statements,  including
the section  captioned  "Factors  That May Affect The Company"  contained in the
Company's  Annual Report on Form 10-KSB/A for the fiscal year ended December 31,
2002.

--------------------


Contact:
     Advanced Biotherapy, Inc.
     Amy Buccellato, 818-883-6716
     www.advancedbiotherapy.com
     --------------------------






</TEXT>
</DOCUMENT>
</SUBMISSION>
